Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Alpmf save search
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Published: 2024-03-11 (Crawled : 13:00) - prnewswire.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
cresemba fda drug children grants
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
| Email alert
Add to watchlist
padcev fda first approved bladder cancer treat advanced plus
FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
FNCTF | $11.128 -20.84% 580
|
Communications
|
| O: 0.68%
H: 0.0%
C: 0.0%
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: -2.79%
H: 0.62%
C: 0.62%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -2.2%
H: 0.0%
C: -0.27%
cresemba fda children
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.59%
H: 0.46%
C: 0.46%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.68%
H: 0.11%
C: -1.16%
xtandi fda review cancer grants
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
Published: 2023-08-05 (Crawled : 04:20) - ivericbio.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
| Email alert
Add to watchlist
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
| Email alert
Add to watchlist
fda approval treatment
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
Published: 2023-07-06 (Crawled : 06:00) - prnewswire.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.86%
H: 0.0%
C: -1.01%
fda license review application grants
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
Published: 2023-05-12 (Crawled : 19:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
| Email alert
Add to watchlist
fda approved treatment
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published: 2023-01-20 (Crawled : 07:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: -1.43%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.07%
H: 1.33%
C: 1.26%
at845 treatment fda disease lifted trial
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:20) - biospace.com/
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | $126.19 0.36% 0.15% 6.2M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda cancer
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | $126.19 0.36% 0.15% 6.2M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda license cancer
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
Published: 2022-08-18 (Crawled : 07:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.8%
H: 0.33%
C: -0.8%
fda drug application
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-27 (Crawled : 08:00) - biospace.com/
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-26 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Published: 2022-06-23 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -0.5%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 4.33%
H: 0.0%
C: -2.44%
fda drug application
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
Published: 2021-10-21 (Crawled : 12:00) - biospace.com/
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: -4.45%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.12%
H: 0.53%
C: 0.06%
fda phase 2 sensor acquired phase 2b hearing loss
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.